• Skip to primary navigation
  • Skip to main content
  • Skip to footer

HepVu

HepVu

An estimated 3.5 million people in the U.S. are living with chronic Hepatitis C infection.

  • INTERACTIVE MAP
  • Location Profiles
  • Find Services
  • News & Updates
  • Events
  • Tools & Resources
Home News & Updates 2022: A Year in Review

2022: A Year in Review

December 14, 2022

As we come to the end of 2022, HepVu takes a step back and looks at this year’s highlights – from new data to insightful infographics and Q&As with viral hepatitis and opioid experts.

As 2022 draws to a close, we here at HepVu would like to thank all our advisors, partners, and members of our community that make this project possible. Thank you to our Advisory Committee and Viral Hepatitis Surveillance Status Report Steering Committee for their persistent guidance, to the organizations like NASTAD and NVHR that partner with us, and to the researchers who help us develop these data. In particular we would like to thank our users—whether in academia, in policy, or people with lived experience—for their continued support. We are excited to head into 2023!

Viral Hepatitis Surveillance Status Report

HepVu and NASTAD released the first-ever assessment of viral hepatitis surveillance practices across U.S. jurisdictions, showing that while public health professionals are doing commendable surveillance work with currently available resources, there is a need for additional funding and resources. In 2021, one-third of U.S. jurisdictions did not have a full-time employee dedicated to viral hepatitis surveillance, even though staff and dedicated time are needed to perform basic surveillance activities. Meanwhile, only half (55%) of jurisdictions were able to produce annual surveillance summaries in 2021, which are important for informing programmatic planning and resource allocation.

This inaugural viral hepatitis surveillance status report benchmarks the state of viral hepatitis surveillance in the U.S. prior to funding dissemination, establishes a baseline to monitor changes over time as federal resources are allocated, assesses how jurisdictions across the U.S. are measuring the impact of viral hepatitis on their communities, and highlights areas in need of additional resources.

State-level Opioid Maps and Data:

HepVu added updated state-level opioid prescription, pain reliever misuse, and overdose mortality data and maps to visualize the relationship between the opioid and viral hepatitis epidemics, as well as illustrate how differences among geographic regions can affect health outcomes. These maps visualize 2020 opioid prescription rates, 2018-2019 pain reliever misuse percent, and 2020 overdose mortality rates across the U.S.

County-level Opioid Maps and Data

HepVu also added updated data and maps on pain reliever misuse and overdose mortality at the county level. These county-level maps visualize 2020 opioid prescription rates per 100 people and 2020 overdose mortality rates per 100,000 people across the U.S.

Opioid data profiles and maps on HepVu can be used to:

  • Monitor progress, trends, and disparities in opioid prescriptions, pain reliever misuse, and overdose mortality and compare side-by-side with maps of social determinants of health visualizing poverty, high school education, and median household income;
  • Compare opioid data among states and counties in your region, as well as viral hepatitis data such as prevalence and mortality;
  • Support research to identify areas that experience an increase in injection drug use and subsequent increases in Hepatitis C transmission;
  • Inform advocacy to improve the health of people who use drugs; and
  • Inform public health planning.

Hepatitis C Treatment Restrictions Data

HepVu added updated data and comparison maps visualizing Hepatitis C treatment restrictions at the state-level from 2017 to 2022, utilizing insights and research findings provided by the Center for Health Law and Policy Innovation (CHLPI) of Harvard Law School and the National Viral Hepatitis Roundtable (NVHR). HepVu also released a new map visualizing the restrictions around prior authorizations, in addition to updated state profiles that show each state Medicaid program’s Hepatitis C treatment restrictions. These new data and visualizations document the changing Hepatitis C treatment restrictions landscape.

The U.S. has made tremendous progress in eliminating or scaling back these treatment restrictions since tracking began in 2017. Due to the continued and diligent work of viral hepatitis organizations such as CHLPI and NVHR many states have eliminated or loosened restrictions.

Our most shared infographics

Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn

A few of our most read blogs this year

  • Chari Cohen On The Importance Of Vaccinating Against Hepatitis B
  • Rita Isabel Lechuga on National Hispanic Hepatitis Awareness Day
  • HepVu’s One Question Series on Viral Hepatitis Elimination: People Who Inject Drugs
  • John W. Ward on the Coalition for Global Hepatitis Elimination (CGHE)

August 11, 2022

Chari Cohen On The Importance Of Vaccinating Against Hepatitis B

Read More

May 12, 2022

Dr. Rita Isabel Lechuga on National Hispanic Hepatitis Awareness Day

Read More

March 21, 2022

Combatting Hepatitis C Among People Who Use Drugs in Appalachia

Read More

December 12, 2022

HepVu Adds 2020 County-Level Opioid Maps and Data

Read More
Share Facebook Twitter LinkedIn Email

Keep Reading

April 14, 2025

What's New in Viral Hepatitis - April 2025

Read More

February 20, 2025

What's New in Viral Hepatitis - February 2025

Read More

December 11, 2024

What's New in Viral Hepatitis - December 2024

Read More

November 21, 2024

World Hepatitis Testing Week 2024 Toolkit

Read More

Sign up for HepVu updates.

Footer

AIDSVu HepVu

HepVu is presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc.

  • About
  • FAQ
  • Data Methods
  • Datasets

Questions?
Info@HepVu.org

Media Inquiries
(202) 854-0480
Media@HepVu.org

Follow Us

  • Facebook
  • Twitter

© 2025 HepVu. All Rights Reserved.

  • Privacy Policy
  • Contact Us

Get HepVu in Your Inbox

Sign up to stay informed on new data, maps, expert Q&As, and infographics about Hepatitis C and opioids where you live.